// App-Quantinova.ai

5697 : Targeting PARP inhibitor resistance with Polθ inhibitors

Researchers

Presenter

  • Diana Zatreanu

Principal Investigators

  • Omar Alkhatib

  • Marie Boursier

  • Harry Finch

  • Lerin Geo

  • Diego Grande

  • Vera Grinkevich

  • Robert Heald

  • Sophie Langdon

  • Jayesh Majithiya

  • Claire McWhirter

  • Niall Martin

  • Shaun Moore

  • Joana Neves

  • Eeson Rajendra

  • Marco Ranzani

  • Theresia Schaedler

  • Martin Stockley

  • Kimberley Wiggins

  • Rachel Brough

  • Sandhya Sridhar

  • Aditi Gulati

  • Nan Shao

  • Luted Badder

  • Daniela Novo

  • Eleanor Knight

  • Rebecca Marlow

  • Syed Haider

  • Elsa Callen

  • Graeme Hewitt

  • Joost Schimmel

  • Remko Prevo

  • Christina Alli

  • Amanda Ferdinand

  • Cameron Bell

  • Peter Blencowe

  • Chris Bot

  • Mathew Calder

  • Mark Charles

  • Jayne Curry

  • Tennyson Ekwuru

  • Andre Nussenzweig

  • Marcel Tijsterman

  • Andrew N. J. Tutt

  • Simon Boulton

  • Geoff Higgins

  • Stephen J. Pettitt

  • Graeme C. M. Smith

  • Christopher J. Lord

Medical Centers

  • Institute for Cancer Research, London, United Kingdom

  • Artios Pharma, Cambridge, United Kingdom

  • National Cancer Institute, Bethesda, MD

  • The Francis Crick Institute, London, United Kingdom

  • Leiden University Medical Center, Leiden, Netherlands, Medical Research Council Oxford Institute of Radiation Oncology, Oxford, United Kingdom

  • CRUK Therapeutic Discovery Laboratories, Cambridge, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Breast cancer type 1 susceptibility protein

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved